Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis

World Journal of Gastroenterology

Volumn 20, Issue 1, 2014, Pages 142-147

  Zhang, Yu ^a   Shi, Zhi Long ^a   Yang, Xia ^a   Yin, Zheng Feng ^a  

^a EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

Author keywords

Circulating tumor cells; Hepatocellular carcinoma; Individualized treatment; Recurrence and metastasis; Surgical treatment

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; RAPAMYCIN; SORAFENIB; THY 1 ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL SELECTION; CIRCULATING TUMOR CELL; DENSITY GRADIENT CENTRIFUGATION; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; METASTASIS; MONITORING; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

CIRCULATING TUMOR CELLS; HEPATOCELLULAR CARCINOMA; INDIVIDUALIZED TREATMENT; RECURRENCE AND METASTASIS; SURGICAL TREATMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84891759256     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i1.142     Document Type: Review

References (50)

1. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253: 453-469 [PMID: 21263310 DOI: 10.1097/ SLA.0b013e31820d944f]
2. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011; 253: 745-758 [PMID: 21475015 DOI: 10.1097/SLA.0b013e3182111195]
3. Zhang Y, Li J, Cao L, Xu W, Yin Z. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol 2012; 39: 449-460 [PMID: 22846862 DOI: 10.1053/j.seminoncol.2012.05.012]
4. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 2011; 11: 2031-2035 [PMID: 21831154 DOI: 10.1111/j.1600-6143.2011.03689]
5. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 2012; 10: 138 [PMID: 22747748 DOI: 10.1186/1479-5876-10-138]
6. Chiappini F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol 2012; 2012: 684802 [PMID: 22690340 DOI: 10.1155/2012/684802]
7. Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics 2007; 4: 741-756 [PMID: 18067413 DOI: 10.1586/1 4789450.4.6.741]
8. Attard G, de Bono JS. Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev 2011; 21: 50-58 [PMID: 21112767 DOI: 10.1016/j.gde.2010.10.010]
9. Paterlini-Bréchot P, Vona G, Bréchot C. Circulating tumorous cells in patients with hepatocellular carcinoma. Clinical impact and future directions. Semin Cancer Biol 2000; 10: 241-249 [PMID: 10936072 DOI: 10.1006/scbi.2000.0323]
10. Morimoto O, Nagano H, Miyamoto A, Fujiwara Y, Kondo M, Yamamoto T, Ota H, Nakamura M, Wada H, Damdinsuren B, Marubashi S, Dono K, Umeshita K, Nakamori S, Sakon M, Monden M. Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood. Surg Today 2005; 35: 1033-1041 [PMID: 16341483 DOI: 10.1007/s00595-005-3077-5]
11. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Bréchot C, Paterlini-Bréchot P. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000; 156: 57-63 [PMID: 10623654 DOI: 10.1016/ S0002-9440(10)64706-2]
12. Min AL, Choi JY, Woo HY, Kim JD, Kwon JH, Bae SH, Yoon SK, Shin SH, Chung YJ, Jung CK. High expression of Snail mRNA in blood from hepatocellular carcinoma patients with extra-hepatic metastasis. Clin Exp Metastasis 2009; 26: 759-767 [PMID: 19533388 DOI: 10.1007/s10585-009-9275-6]
13. Nel I, Baba HA, Ertle J, Weber F, Sitek B, Eisenacher M, Meyer HE, Schlaak JF, Hoffmann AC. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl Oncol 2013; 6: 420-428 [PMID: 23908685]
14. Wu LJ, Pan YD, Pei XY, Chen H, Nguyen S, Kashyap A, Liu J, Wu J. Capturing circulating tumor cells of hepatocellular carcinoma. Cancer Lett 2012; 326: 17-22 [PMID: 22842097 DOI: 10.1016/j.canlet.2012.07.024]
15. Xu W, Cao L, Chen L, Li J, Zhang XF, Qian HH, Kang XY, Zhang Y, Liao J, Shi LH, Yang YF, Wu MC, Yin ZF. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 2011; 17: 3783-3793 [PMID: 21527564 DOI: 10.1158/1078-0432.CCR-10-0498]
16. Melloul E, Lesurtel M, Carr BI, Clavien PA. Developments in liver transplantation for hepatocellular carcinoma. Semin Oncol 2012; 39: 510-521 [PMID: 22846868 DOI: 10.1053/j.seminoncol.2012.05.008]
17. Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC, Wong J. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg 2011; 254: 569-576 [PMID: 21892074 DOI: 10.1097/ SLA.0b013e3182300a1d]
18. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J, Fan J. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013; 57: 1458-1468 [PMID: 23175471 DOI: 10.1002/hep.26151]
19. Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 2013; 133: 2165-2171 [PMID: 23616258 DOI: 10.1002/ijc.28230]
20. Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J, Wang J, Zhang D, Cheng S, Liu S. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology 2013; 144: 1031-1041.e10 [PMID: 23376424 DOI: 10.1053/j.gastro.2013.01.046]
21. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 [PMID: 19058754 DOI: 10.1016/ S1470-2045(08)70284-5]
22. Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol 2013; 9: 1533-1548 [PMID: 24106903 DOI: 10.2217/fon.13.171]
23. Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int 2011; 31: 740-743 [PMID: 21457447 DOI: 10.1111/j.1478-3231.2010.02441]
24. Williet N, Dubreuil O, Boussaha T, Trouilloud I, Landi B, Housset M, Botti M, Rougier P, Belghiti J, Taieb J. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. World J Gastroenterol 2011; 17: 2255-2258 [PMID: 21633538 DOI: 10.3748/wjg.v17. i17.2255]
25. Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B. Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol 2011; 2011: 791013 [PMID: 22135750 DOI: 10.4061/2011/791013]
26. Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a costbenefit analysis while awaiting data on sorafenib safety. Hepatology 2010; 51: 165-173 [PMID: 19877181 DOI: 10.1002/ hep.23260]
27. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL. Anterior approach for difficult major right hepatectomy. World J Surg 1996; 20: 314-337; discussion 318 [PMID: 8661837 DOI: 10.1007/ s002689900050]
28. Belghiti J, Guevara OA, Noun R, Saldinger PF, Kianmanesh R. Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization. J Am Coll Surg 2001; 193: 109-111 [PMID: 11442247 DOI: 10.1016/ S1072-7515(01)00909-7]
29. Wu TJ, Wang F, Lin YS, Chan KM, Yu MC, Lee WC. Right hepatectomy by the anterior method with liver hanging versus conventional approach for large hepatocellular carcinomas. Br J Surg 2010; 97: 1070-1078 [PMID: 20632274 DOI: 10.1002/bjs.7083]
30. Jiang C, Wang Z, Xu Q, Wu X, Ding Y. Inferior Right Hepatic Vein-preserving Major Right Hepatectomy for Hepatocellular Carcinoma in Patients with Significant Fibrosis or Cirrhosis. World J Surg 2014; 38: 159-167 [PMID: 24081537 DOI: 10.1007/s00268-013-2240-1]
31. Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, Tsukada K, Saiki I. Increased surgical stress promotes tumor metastasis. Surgery 2003; 133: 547-555 [PMID: 12773983 DOI: 10.1067/msy.2003.141]
32. Oe H, Kaido T, Mori A, Onodera H, Imamura M. Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats. Hepatogastroenterology 2005; 52: 1393-1397 [PMID: 16201081]
33. Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR, D'Angelica M, Blumgart LH, Tanabe KK, Dematteo RP. Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 2006; 13: 353-362 [PMID: 16474912 DOI: 10.1245/ASO.2006.03.060]
34. Rupertus K, Kollmar O, Scheuer C, Junker B, Menger MD, Schilling MK. Major but not minor hepatectomy accelerates engraftment of extrahepatic tumor cells. Clin Exp Metastasis 2007; 24: 39-48 [PMID: 17260102 DOI: 10.1007/ s10585-006-9054-6]
35. Van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, Te Velde EA, Voest EE, van Diest PJ, Borel Rinkes IH. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 2005; 42: 165-175 [PMID: 15962318 DOI: 10.1002/hep.20739]
36. Van der Bilt JD, Kranenburg O, Borren A, van Hillegersberg R, Borel Rinkes IH. Ageing and hepatic steatosis exacerbate ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Ann Surg Oncol 2008; 15: 1392-1398 [PMID: 18335279 DOI: 10.1245/s10434-007-9758-0]
37. Van der Bilt JD, Soeters ME, Duyverman AM, Nijkamp MW, Witteveen PO, van Diest PJ, Kranenburg O, Borel Rinkes IH. Perinecrotic hypoxia contributes to ischemia/ reperfusion-accelerated outgrowth of colorectal micrometastases. Am J Pathol 2007; 170: 1379-1388 [PMID: 17392176 DOI: 10.2353/ajpath.2007.061028]
38. Nijkamp MW, Hoogwater FJ, Govaert KM, Steller EJ, Verheem A, Kranenburg O, Borel Rinkes IH. A role for CD95 signaling in ischemia/reperfusion-induced invasion and outgrowth of colorectal micrometastases in mouse liver. J Surg Oncol 2011; 104: 198-204 [PMID: 21506133 DOI: 10.1002/jso.21915]
39. Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, Lee TK, Poon RT, Fan ST. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases--activation of cell invasion and migration pathways. Liver Transpl 2007; 13: 1669-1677 [PMID: 18044786 DOI: 10.1002/lt.21193]
40. Nagai S, Facciuto M, Mori S, Ninomiya M, Rocca JP, Contreras-Saldivar A, Schwartz ME, Florman SS. WITHDRAWN: Recurrence prediction of hepatocellular carcinoma after liver transplantation by ischemia time and tumor characteristics. J Hepatol 2013 Feb 17; Epub ahead of print [PMID: 23422778 DOI: 10.1016/j.jhep.2013.02.003]
41. Giuliante F, Ardito F, Pulitanò C, Vellone M, Giovannini I, Aldrighetti L, Ferla G, Nuzzo G. Does hepatic pedicle clamping affect disease-free survival following liver resection for colorectal metastases? Ann Surg 2010; 252: 1020-1026 [PMID: 21107113 DOI: 10.1097/SLA.0b013e3181f66918]
42. Xia F, Lau WY, Xu Y, Wu L, Qian C, Bie P. Does hepatic ischemia-reperfusion injury induced by hepatic pedicle clamping affect survival after partial hepatectomy for hepatocellular carcinoma? World J Surg 2013; 37: 192-201 [PMID: 22965538 DOI: 10.1007/s00268-012-1781-z]
43. Fan ZC, Yan J, Liu GD, Tan XY, Weng XF, Wu WZ, Zhou J, Wei XB. Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis. Cancer Res 2012; 72: 2683-2691 [PMID: 22454286 DOI: 10.1158/0008-5472. CAN-11-3733]
44. Feng YX, Wang T, Deng YZ, Yang P, Li JJ, Guan DX, Yao F, Zhu YQ, Qin Y, Wang H, Li N, Wu MC, Wang HY, Wang XF, Cheng SQ, Xie D. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 2011; 53: 483-492 [PMID: 21274870 DOI: 10.1002/hep.24075]
45. Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study. Hepatol Res 2013 May 14; Epub ahead of print [PMID: 23672310 DOI: 10.1111/hepr.12159]
46. Yan J, Tan C, Gu F, Jiang J, Xu M, Huang X, Dai Z, Wang Z, Fan J, Zhou J. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase. Liver Transpl 2013; 19: 507-520 [PMID: 23408515 DOI: 10.1002/lt.23619]
47. Huang L, Li GM, Zhu JY, Li Z, Li T, Leng XS. Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study. Onco Targets Ther 2012; 5: 457-462 [PMID: 23277740 DOI: 10.2147/OTT.S31387]
48. Finn RS. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer 2012; 1: 247-256 [PMID: 24159589 DOI: 10.1159/000343839]
49. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243 [PMID: 20187107 DOI: 10.1002/hep.23437]
50. Lehmann K, Clavien PA. History of hepatic surgery. Surg Clin North Am 2010; 90: 655-664 [PMID: 20637939 DOI: 10.1016/j.suc.2010.04.018]